<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Trisalus Life Sciences Inc. — News on 6ix</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc</link>
<description>Latest news and press releases for Trisalus Life Sciences Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/trisalus-life-sciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ca1c78dffbe2df11c96a.webp</url>
<title>Trisalus Life Sciences Inc.</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc</link>
</image>
<item>
<title>TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-to-host-first-quarter-2026-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-to-host-first-quarter-2026-financial-results-conference-call</guid>
<pubDate>Tue, 28 Apr 2026 20:05:00 GMT</pubDate>
<description>WESTMINSTER, Colo., April 28, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. A press release detailing the r</description>
</item>
<item>
<title>TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-to-present-new-data-at-the-2026-society-of-interventional-radiology-annual-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-to-present-new-data-at-the-2026-society-of-interventional-radiology-annual-scientific-meeting</guid>
<pubDate>Thu, 09 Apr 2026 20:05:00 GMT</pubDate>
<description>WESTMINSTER, Colo., April 09, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada.</description>
</item>
<item>
<title>TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-appoints-richard-marshall-md-as-chief-medical-officer</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-appoints-richard-marshall-md-as-chief-medical-officer</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology</description>
</item>
<item>
<title>TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-publication-demonstrating-enhanced-delivery-and-immune-activation-with-nelitolimod-delivered-with-pressure-enabled-drug-delivery-in-liver-tumor-models</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-publication-demonstrating-enhanced-delivery-and-immune-activation-with-nelitolimod-delivered-with-pressure-enabled-drug-delivery-in-liver-tumor-models</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with</description>
</item>
<item>
<title>TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-reports-fourth-quarter-and-year-end-2025-results-and-reaffirms-2026-revenue-guidance-38</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-reports-fourth-quarter-and-year-end-2025-results-and-reaffirms-2026-revenue-guidance-38</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the</description>
</item>
<item>
<title>TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-to-host-fourth-quarter-2025-financial-results-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-to-host-fourth-quarter-2025-financial-results-conference-call</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Conference Call and Webcast Scheduled for Thursday, March 5, 2026 at 4:30 PM WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq:</description>
</item>
<item>
<title>TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-pricing-of-dollar400-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-pricing-of-dollar400-million-public-offering</guid>
<pubDate>Fri, 20 Feb 2026 13:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., February 20, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced it has priced its previously announced underwritten public offering of 9,756,100 shares of its common stock at a public offering price of $4.10 per share. All of the shares in the offering ar</description>
</item>
<item>
<title>TriSalus Life Sciences Proposes Public Offering</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-proposes-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-proposes-public-offering</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>WESTMINSTER, Colo., February 19, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by TriSalus. In addition, TriSalus</description>
</item>
<item>
<title>TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-appoints-veteran-140000617</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-appoints-veteran-140000617</guid>
<pubDate>Mon, 09 Feb 2026 14:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., February 09, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors.</description>
</item>
<item>
<title>TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-preliminary-120000221</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-preliminary-120000221</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., January 12, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-host-virtual-210100601</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-host-virtual-210100601</guid>
<pubDate>Thu, 04 Dec 2025 21:01:00 GMT</pubDate>
<description>WESTMINSTER, Colo., December 04, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cu</description>
</item>
<item>
<title>TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-launches-trinav-130000958</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-launches-trinav-130000958</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., November 18, 2025--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the launch of the TriNav® XP Infusion System, the latest advancement in the company’s portfolio of pressure-enabled drug delivery systems designed to improve therapy delivery in varying vascular environments.</description>
</item>
<item>
<title>TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-reports-third-210100651</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-reports-third-210100651</guid>
<pubDate>Thu, 13 Nov 2025 21:01:00 GMT</pubDate>
<description>DENVER, November 13, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update.</description>
</item>
<item>
<title>TriSalus Life Sciences to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-participate-upcoming-210500250</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-participate-upcoming-210500250</guid>
<pubDate>Tue, 11 Nov 2025 21:05:00 GMT</pubDate>
<description>WESTMINSTER, Colo., November 11, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the following investor conferences in November:</description>
</item>
<item>
<title>TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-host-virtual-130000048</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-host-virtual-130000048</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., November 10, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (Universi</description>
</item>
<item>
<title>TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-host-third-120000367</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-host-third-120000367</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., October 30, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss</description>
</item>
<item>
<title>TriSalus Life Sciences to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-participate-upcoming-120000839</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-participate-upcoming-120000839</guid>
<pubDate>Thu, 28 Aug 2025 12:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., August 28, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the follo</description>
</item>
<item>
<title>TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-reports-second-200100131</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-reports-second-200100131</guid>
<pubDate>Tue, 12 Aug 2025 20:01:00 GMT</pubDate>
<description>DENVER, August 12, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update.</description>
</item>
<item>
<title>TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-publication-120000136</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-announces-publication-120000136</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>WESTMINSTER, Colo., August 11, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympto</description>
</item>
<item>
<title>TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-participate-canaccord-200500511</link>
<guid isPermaLink="true">https://6ix.com/company/trisalus-life-sciences-inc/news/trisalus-life-sciences-participate-canaccord-200500511</guid>
<pubDate>Wed, 30 Jul 2025 20:05:00 GMT</pubDate>
<description>WESTMINSTER, Colo., July 30, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 9:00 a.m. ET. Management will also host investor meetings during</description>
</item>
</channel>
</rss>